Key Segmentation:
By Assay Type
-
Cell-Based Assays
-
Reporter Gene Assays
-
Binding & Immunoassays
-
Molecular & Biochemical Assays
By Product & Service
-
Kits & Reagents
-
Instruments
-
Services
By Cell Therapy Type
-
CAR-T Cell Therapy
-
Stem Cell Therapy
-
TIL & NK Cell Therapy
-
Dendritic Cell & Other Cell Therapies
By End User
-
Pharmaceutical & Biotechnology Companies
-
CDMOs & CROs
-
Academic & Research Institutes
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Assay Type X Cell Therapy Type)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key Players include Charles River Laboratories International, Inc., Lonza Group AG, Thermo Fisher Scientific Inc., Sartorius AG, and WuXi AppTec Co., Ltd., among others.
Key opportunities include rising cell therapy pipelines, outsourced assay development, automated testing, reporter gene technologies, and demand for GMP-compliant potency testing.
The market is driven by the rapid expansion of the global cell therapy pipeline, tightening FDA and EMA potency assurance requirements, and rising outsourcing of assay development to CDMOs and CROs.
The Services segment dominated the Cell Therapy Potency Assays Market in 2025, accounting for approximately 51.80% market share.
The North America region dominated the Cell Therapy Potency Assays Market in 2025 with a 42.50% share, driven by its dense concentration of commercially approved cell therapies and advanced FDA regulatory framework.
